I n this issue of the Journal Dr. Ventafridda and his colleagues report the results of a prospective study "to document how long before death symptoms appear that patients term unendurable and that are controllable only with sedation-induced sleep" (12) .
One hundred and fifty-four consecutive patients with metastatic cancer no longer responsive to antitumor therapy were entered into the study. Data are reported on 120 patients dying prior to data analysis. The patients were cared for on the large, well-staffed home care program of the Palliative Care Division of the National Cancer Institute of Milan.
Forty-three of 123 episodes of "unendurable" symptoms (35 percent) were controlled through the therapeutic intervention of the home care team. Eighty episodes of unendurable suffering, occuring in 63 patients (52.5 percent of the study sample), could not, however, be controlled, leading the physicians to seek relief through sedation using morphine, methadone, diazepam, chlorpromazine, or haloperidol, alone or in combination. While details of their prescribing practice are not given, the authors state that "dosages were progressively titrated by the hour or day until the symptom was controlled", with death occurring 49 hours (mean) later.
They comment further that these patients were sedated at home rather than being admitted to an inpatient hospice or palliative care unit because "there are no differences in symptom control in home or hospital setting" (11) .
This disturbing paper suggests that 23 years after the birth of the modern hospice movement the majority of cancer patients cared for by our best equipped palliative care services may expect to encounter a crescendo of uncontrollable suffering manageable only through sleep induction prior to death.
Does this reflect the general experience of other programs? Dr. Ventafridda reports that all
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"unendurable" episodes were accounted for by four symptoms: dyspnea, pain, delirium, and vomiting. What about pain? In this study 25.8 percent of dying cancer patients had "unendurable" pain necessitating sedation. This stands in contrast to Hinton's finding that 82 percent of patients dying with malignant disease in general hospital wards in Britain had adequate pain relief. Futhermore Hinton's study was published in 1963, prior to the advent of the hospice movement with its assured beneficial impact on symptom control (2) .
Patient selection factors may account for the poorer pain concrol in the Milan -patients. Patient populations more relevant to the Milan data may be found in hospice programs admitting patients whose symptoms have been found difficult to control elsewhere.
Such a study is reported by Saunders who documented 98 of 100 consecutive terminal cancer patient deaths at St. Christopher's Hospice 0978-79) as peaceful (7) . Of these, 60 patients were peaceful for 24 hours or longer; 27 patients had transient distress recorded between four and 24 hours prior to death, and 13 had transient distress recorded within four hours of death. The level of consciousness recorded for these 100 patients during the 24 hours before death were 10 patients alert, 67 patients drowsy, rousable or semi-conscious, and 23 patients unrousable, unresponsive, or unconscious. Thus less than one quarter of all cancer patients in this St. Christopher's Hospice series died in a comatose state, including those patients unconscious due to tumor, metabolic state, and all other causes combined, while more than half the Milan patients died in iatrogenic coma.
While it may be true that cancer patients experience pain with increasing frequency and severity as death approaches as McKegney suggests (4), this does not indicate that the pain becomes more difficult to treat. Indeed our expe-6 • rience on the Royal Victoria Hospital Palliative Care Service (RVH PCS) home care and inpatient programs parallels that of Twycross and Lack who state, "Pain will not be troublesome at the very end if control has previously been good. There is no final crescendo of pain. On the contrary, analgesic requirements may decrease" (8) .
What of dyspnea? Ventafridda reports that 27.5 percent of his dying cancer patients required sedation to manage intolerable dyspnea, while in Saunders' series of 100 consecutive cancer patient deaths one patient died with unrelieved dyspnea and four had transient dyspnea within four hours of death. The exact incidence of dyspnea in the St. Christopher's series is not stated, nor is the frequency of need to sedate to unconsciousness to obtain patient comfort.
The Milan study is unsettling because it runs counter to common experience. It challenges our assumptions. In the RVH PCS team experience the need to sedate to unconsciousness for symptom relief in the dying cancer patient is extremely rare. Lichter, in New Zealand, reports an experience similar to our own (3).
It is not the first time that the fledgling field of palliative/hospice care has generated widely divergent data in studies relating to the dying. For example, Ventafridda reports no difference in symptom control in home or hospital (11) , while the National Hospice Study found that patients in hospital based programs were significantly less likely to be in pain that those in home care programs (p<O.Ol) (5) . Similarly, the National Hospice Study documented a 70.2 percent incidence of dyspnea (6) , an incidence more than double that reported by Twycross and Lack, (30 percent) in 1984 (9) and significantly higher than the same authors reported in 1990 (50 percent) (10) .
What are the variables responsible for the apparent discrepancies in experience of terminal distress alluded to above? As already noted, patient selection factors may be playing a major role. Two things are clear. First, the findings reported by Dr. Ventafridda and his colleagues should stimulate others to record their experience in this regard. Second, this study underscores the need for more refined research tools, such as the Edmonton staging system for cancer pain proposed by Bruera et al. (1) , that will enable us to more accurately define salient population characteristics that have an impact on the prevalence of symptoms and the need for specific therapeutic interventions .
